BIRC5 and lung adenocarcinoma: We observed a significant decrease in survivin levels after platinum plus pemetrexed combination in patients with lung adenocarcinoma (26.22/0–626.46/pg/ml before vs. 0/0–114.36/pg/ml after chemotherapy, p = 0.01), but there was no significant change in either bevacizumab-combined treatment in ADC or in small cell lung cancer (Figure 5).